Demchyshyn L L, McConkey F, Niznik H B
Departments of Psychiatry and Pharmacology and Institute of Medical Science, University of Toronto, Ontario, Canada M5S 1AB.
J Biol Chem. 2000 Aug 4;275(31):23446-55. doi: 10.1074/jbc.M000157200.
The mammalian dopamine D1-like receptor gene family is comprised of two members, termed D1/D1A and D5/D1B. In an attempt to define the role of the carboxyl terminal (CT) tail in the expression of D5 subtype-specific pharmacological and constitutive activity profiles, we examined a series of D5 receptor chimeras in which only the CT tail was swapped with corresponding sequences encoding human/vertebrate D1-like receptors. D5/D1(CT) or D5/D1D(CT) tail substitution mutants displayed a rank order of potency and agonist affinities virtually mimicking wild-type (wt) D1 receptors, as indexed by both ligand binding and dopamine-stimulated cAMP accumulation assays, and, similar to wt D1 receptors, did not exhibit receptor constitutive activity or responsiveness to inverse agonists. D1/D5(CT) or D1/D1D(CT) tail receptor mutants displayed agonist pharmacological and functional characteristics not significantly different from parental D1 or mutant D5/D1(CT) and D5/D1D(CT) receptors. The affinities for numerous antagonists remained essentially unchanged for all receptor chimeras relative to parental wt receptors. A series of stepwise D5-CT-tail truncation/deletion mutants identified the region encoded by amino acids 438-448 and particularly Gln(439), as necessary and sufficient for the full expression of high affinity agonist and functional D5 receptor characteristics. Site-directed mutagenesis of the highly conserved D5/D1B receptor residue Gln(439)-(Ala/Ile), converts the full-length D5 receptor to one displaying "super" D5 characteristics with expressed affinities for discriminating agonists approximately 4- to 5-fold higher than wt D5 but without any concomitant increases of agonist-independent basal cAMP accumulation or intrinsic activity. Taken together, these data suggest that, in addition to other well characterized receptor domains, the agonist pharmacological and functional signature of the D5/D1B receptor is modulated by sequence-specific motifs within the CT tail and that one conserved amino acid in this region can further regulate D5 agonist high affinity binding interactions independent of receptor constitutive activity.
哺乳动物多巴胺D1样受体基因家族由两个成员组成,分别称为D1/D1A和D5/D1B。为了确定羧基末端(CT)尾巴在D5亚型特异性药理学和组成性活性谱表达中的作用,我们研究了一系列D5受体嵌合体,其中只有CT尾巴与编码人/脊椎动物D1样受体的相应序列进行了交换。D5/D1(CT)或D5/D1D(CT)尾巴替代突变体表现出的效价和激动剂亲和力顺序实际上模仿了野生型(wt)D1受体,这通过配体结合和多巴胺刺激的cAMP积累试验得到证实,并且与wt D1受体相似,没有表现出受体组成性活性或对反向激动剂的反应性。D1/D5(CT)或D1/D1D(CT)尾巴受体突变体表现出的激动剂药理学和功能特性与亲本D1或突变体D5/D1(CT)和D5/D1D(CT)受体没有显著差异。相对于亲本wt受体,所有受体嵌合体对多种拮抗剂的亲和力基本保持不变。一系列逐步的D5-CT尾巴截短/缺失突变体确定了由氨基酸438-448特别是Gln(439)编码的区域,该区域对于高亲和力激动剂和功能性D5受体特性的完全表达是必要且充分的。将高度保守的D5/D1B受体残基Gln(439)定点突变为(Ala/Ile),可将全长D5受体转变为具有“超级”D5特性的受体,其对区分激动剂的表达亲和力比wt D5高约4至5倍,但不会伴随激动剂非依赖性基础cAMP积累或内在活性的任何增加。综上所述,这些数据表明,除了其他特征明确的受体结构域外,D5/D1B受体的激动剂药理学和功能特征受CT尾巴内的序列特异性基序调节,并且该区域中的一个保守氨基酸可以进一步调节D5激动剂的高亲和力结合相互作用,而与受体组成性活性无关。